ArticleScientific reports2025
Risk factors of adverse pregnancy outcomes in patients with immunoglobulin A nephropathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregnancy and childbirth are major concerns for women with immunoglobulin A nephropathy (IgAN), because it peaks in their child-bearing age. To provide evidence for optimal pre-conception care, we investigated whether the disease control status, assessed by blood pressure and/or urine protein level, is associated with adverse pregnancy outcomes. This case-control study used data from 924,238 patients with chronic kidney disease obtained from a hospital claims database. We included 297 pregnancies with IgAN and collected data on antihypertensive medications and glucocorticoid therapy within six months before conception as the exposures. The outcomes were hypertensive disorders of pregnancy (HDP) that required intravenous nicardipine and preterm delivery. We estimated the adjusted odds ratios (aORs) using multivariable logistic regression. The prescriptions of antihypertensive medications other than renin-angiotensin-aldosterone system inhibitors (RASi) were significantly associated with both severe HDP requiring intravenous nicardipine (aOR: 5.01, 95% confidence interval [CI]: 1.43-17.5) and preterm delivery (aOR: 6.45, 95% CI: 1.81-23.0), compared with those of only RASi. No significant associations were observed between glucocorticoid therapy and outcomes. Regarding pre-conception care, our findings suggest that pre-conception antihypertensive medication use, as a surrogate marker for underlying hypertension, may help identify women with IgAN at higher risk of adverse pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.